MacroGenics Reports Q2 2025 Financials, Updates Key Strategic Priorities

Thursday, Aug 14, 2025 4:02 pm ET1min read
MGNX--

MacroGenics reported Q2 2025 financial results, with a cash runway through H1 2027. The company received a $70m upfront payment from Sagard Healthcare Partners under a royalty purchase agreement for ZYNYZ. Newly-appointed CEO Eric Risser outlined key strategic priorities for 2025 and 2026, including determining the development path for lorigerlimab, advancing MGC026 and MGC028 programs, and submitting an IND application for MGC030.

MacroGenics Reports Q2 2025 Financials, Updates Key Strategic Priorities

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet